Clinical Report: Evolving Clonal Resistance Mechanisms in EGFR-Mutant Lung Adenocarcinoma

Background

Lung adenocarcinoma is the most prevalent subtype of non-small cell lung cancer (NSCLC), with EGFR mutations being a significant driver of tumorigenesis. Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) have improved patient outcomes, yet acquired resistance remains a major challenge. Understanding the mechanisms of resistance is crucial for optimizing treatment.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• A 62-year-old man with EGFR L858R mutation developed multiple bypass resistance mechanisms during treatment.
• Resistance mechanisms included MET amplification, BRAF V600E mutation, and RET fusion.
• Dynamic next-generation sequencing revealed a sequential trajectory of resistance clone evolution.
• Genotype-guided treatment modifications led to an 11-month progression-free survival with aumolertinib plus savolitinib.
• Subsequent treatment with selpercatinib and chemotherapy resulted in transient disease stabilization.
• The patient died from complications related to progressive disease.

Clinical Implications

The case highlights the necessity of serial biopsies and next-generation sequencing to monitor resistance evolution in patients with EGFR-mutant lung adenocarcinoma.

Conclusion

This case illustrates the complexity of resistance mechanisms in EGFR-mutant lung adenocarcinoma.

Related Resources & Content

1. Frontiers in Oncology, 2026 -- Emergence of EML4-ALK Fusion and BRAF V600G Dual Pathway Activation After Osimertinib Resistance in Lung Adenocarcinoma: A Case Study of Successful Lorlatinib Treatment
2. Frontiers in Oncology, 2026 -- Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids
3. The ASCO Post, 2022 -- Acquired EGFR Inhibitor Resistance Alterations Identified in ctDNA Analysis in Patients With Refractory Metastatic Colorectal Cancer
4. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC | New England Journal of Medicine
5. Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC -- mechanisms and evolving treatment approaches | Nature Reviews Clinical Oncology
6. the asco post — Therapy With a Tyrosine Kinase Inhibitor for EGFR-Variant Lung Adenocarcinoma: Lessons From Chronic Myeloid Leukemia?
7. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC | New England Journal of Medicine
8. Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches | Nature Reviews Clinical Oncology
9. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial - ScienceDirect